) by KRG-TS was very strongly inhibited by Rp-8-Br-cAMPS compared with that by Rp-8-BrcGMPS. These results suggest that the inhibitory effect of [Ca 2þ ] i mobilization by KRG-TS is more strongly dependent on a cAMP/PKA pathway than a cGMP/PKG pathway. KRG-TS also inhibited the release of adenosine triphosphate and serotonin. In addition, only G-Rg3 of protopanaxadiol in KRG-TS inhibited thrombin-induced platelet aggregation. Conclusion: These results strongly indicate that KRG-TS is a potent beneficial compound that inhibits [Ca 2þ ] i mobilization in thrombineplatelet interactions, which may result in the prevention of platelet aggregation-mediated thrombotic disease.
Introduction
Platelet aggregation is absolutely essential for the formation of a hemostatic plug when normal blood vessels are injured. However, the interactions between platelets and thrombin can also cause circulatory disorders, such as thrombosis, atherosclerosis, and myocardial infarction [1] . Accordingly, inhibition of the platelete thrombin interaction might be a promising approach for the prevention of thrombosis. It is well-known that thrombin, a platelet agonist, stimulates platelet aggregation by binding to the Gq-coupled proteinase-activated receptor, which is involved in activating phospholipase C-b (PLC-b Ginseng, the root of Panax ginseng C.A. Meyer, has been used frequently in traditional Oriental medicine, and is known to possess various pharmacological effects such as anti-inflammatory, antioxidation, antitumor, antidiabetes, and antihepatotoxicity [11, 12] . Recently, it has been reported that Korean Red Ginseng (KRG) also has an effect on cardiovascular disease, which is characterized by reduction in blood pressure and arterial stiffness by inhibition of Rho kinase activity [13] , anticoagulation by prolonging prothrombin and activated partial thromboplastin times [14] , endothelium relaxation by the nitric oxideecGMP pathway [15] , and inhibition of hypercholesterolemia-induced platelet aggregation [16] . In a previous report, it has been demonstrated that total saponin from KRG (KRG-TS) inhibits the production of thromboxane A 2 (TXA 2 ) in platelet-mediated thrombotic disease by suppressing the activities of cyclooxygenase-1 (COX-1) and thromboxane A 2 synthase (TXAS) [17] . In addition, KRG-TS was reported to be involved in increasing the cAMP level and subsequent reduction of [Ca 2þ ] i mobilization in thrombin-induced rat platelet aggregation [18] . With regard to the effects of ginsenosides on platelet aggregation, it is well-known that ginsenoside Rg3 (G-Rg3) and its chemical derivatives (dihydroxyginsenoside Rg3 and ginsenoside Rp1) exhibit antiplatelet effects by regulating the aggregation-inhibiting molecule (cAMP) and aggregation-stimulating molecules (extracellular kinase 2, tyrosine kinase-dependent phosphoproteins, TXA 2 
, and G-Rh2 (20R)] and protopanaxatriol saponins [PPTSs; G-Re, G-Rf, G-Rg1, G-Rg2 (20R), and G-Rh1 (20S)] were purchased from Ambo Institute (Daejeon, Korea).
Preparation of washed human platelets
Human-platelet-rich plasma (PRP) anticoagulated with acide citrateedextrose solution (0.8% citric acid, 2.2% sodium citrate, and 2.45% glucose) was obtained from Korean Red Cross Blood Center (Changwon, Korea). The PRP was centrifuged for 10 min at 125g to remove little red blood cells, and was centrifuged for another 10 min at 1,300g to obtain the platelets. The platelets were washed two times with washing buffer (138mM NaCl, 2.7mM KCl, 12mM NaHCO 3 , 0.36mM NaH 2 PO 4 , 5.5mM glucose, and 1mM EDTA; pH 6.5). The washed platelets were then resuspended in suspension buffer (138mM NaCl, 2.7mM KCl, 12mM NaHCO 3 , 0.36mM NaH 2 PO 4 , 0.49mM MgCl 2 , 5.5mM glucose, and 0.25% gelatin; pH 6.9) to make up a final concentration of 5 Â 10 8 /mL. All of the aforementioned procedures were carried out at 25 C to avoid platelet aggregation at low temperatures. The Korea National Institute for Bioethics Policy Public Institutional Review Board (Seoul, Korea) approved these experiments (PIRB12-072).
Measurement of platelet aggregation
Washed platelet (10 8 /mL) were preincubated for 3 min at 37 C in the presence of 2mM exogenous CaCl 2 with or without (KRG-TS, A-kinase/G-kinase inhibitor), and then stimulated with thrombin (0.05 U/mL) for 5 min. Aggregation was monitored using an aggregometer (Chrono-log Corporation) at a constant stirring speed of 1,000 rpm. Each aggregation rate was evaluated as an increase in light transmission. The suspension buffer was used as the reference (transmission 0). KRG-TS was dissolved in the platelet suspension buffer (pH 6.9).
Determination of cytosolic-free Ca 2þ
PRP was incubated with 5mM Fura 2-AM at 37 C for 60 min. Because Fura 2-AM is light sensitive, the tube containing the PRP was covered with aluminum foil during loading. The Fura 2-loaded washed platelets were prepared using the aforementioned procedure and 10 8 platelets/mL were preincubated for 3 min at 37 C with or without KRG-TS in the presence of 2mM CaCl 2 , and then stimulated with thrombin (0.05 U/mL) for 5 min to evaluate [Ca 2þ ] i . Fura 2 fluorescence was measured using a spectrofluorometer (SFM 25; BioTek Instruments, Milan, Italy) with an excitation wavelength that was changed every 0.5 s from 340 nm to 380 nm. The emission wavelength was set at 510 nm. The [Ca 2þ ] i values were calculated using the method suggested by Schaeffer and Blaustein [22] .
Determination of ATP and serotonin release
The washed platelets (10 8 /mL) were preincubated for 3 min at 37 C with or without (KRG-TS, A-kinase/G-kinase inhibitor, A-kinase/G-kinase activator) in the presence of 2mM CaCl 2 , and then stimulated with thrombin (0.05 U/mL). The reaction was terminated and the mixture was centrifused with 200xg at 4 C for 10 min. The supernatants were used for the ATP and serotonin release assays. ATP release was measured in a luminometer (GloMax 20/ /mL) were preincubated with or without KRG-TS in the presence of 2mM CaCl 2 for 3 min and then stimulated with thrombin (0.05 U/mL) for 5 min at 37 C. The reactions were terminated by adding an equal volume (250 mL) of lysis buffer (20mM TriseHCl, 150mM NaCl, 1mM Na 2 EDTA, 1mM ethylene glycol tetraacetic acid, 1% Triton X-100, 2.5mM sodium pyrophosphate, 1mM serine/threonine phosphatase inhibitor b-glycerophosphate, 1mM ATPase, alkaline and acid phosphatase, protein phosphotyrosine phosphatase inhibitor Na 3 VO 4 , 1 mg/mL serine and cysteine protease inhibitor leupeptin, and 1mM serine protease and acetylcholinesterase inhibitor phenylmethanesulfonyl fluoride; pH 7.5). Platelet lysates containing the same protein (15 mg) were used for analysis. Protein concentrations were measured using a bicinchoninic acid protein assay kit (Pierce Biotechnology, Waltham, MA, USA). The effects of various substances on PKA catalytic subunit (PKAc) and IP 3 RI phosphorylation were analyzed by Western blotting. A 6e8% sodium dodecyl sulfate polyacrylamide gel electrophoresis was used for electrophoresis and a PVDF membrane was used for protein transfer from the gel. The dilutions for antiphospho-IP 3 RI (Ser 1756 ), antiphospho-PKAc (Thr  197 ) , and antirabbit IgGeHRP were 1:1,000, 1:1,000, and 1:10,000, respectively. The membranes were visualized using ECL. Blots were analyzed using the Quantity One version 4.5 software (BioRad, Hercules, CA, USA).
Statistical analyses
The experimental results were expressed as the mean AE standard deviation accompanied by the number of observations. Data were assessed by analysis of variance. If this analysis indicated significant differences among the group means, then each group was compared by the NewmaneKeuls method. Statistical analysis was performed using SPSS 21.0.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was taken to be significant.
Results

Effects of KRG-TS on thrombin-induced human platelet aggregation
The concentration of thrombin-induced maximal human platelet aggregation was approximately 0.05 U/mL (Fig. 1A) . Therefore, 0.05 U/mL thrombin was used as the human platelet agonist in this study. The light transmission in response to various concentrations of KRG-TS in intact platelets was 1.3 AE 0.6% (at 25 mg/mL of KRG-TS), 1.3 AE 0.6% (at 50 mg/mL of KRG-TS), 1.3 AE 0.6% (at 100 mg/mL of KRG-TS), and 1.3 AE 0.6% (at 150 mg/mL of KRG-TS), which was not significantly different from that observed in resting platelets [1.0 AE 0.0%; Fig. 1B(aee) ]. This result indicated that KRG-TS alone did not have an effect on platelet aggregation. When washed human platelets (10 8 /mL) were activated with thrombin, the aggregation rate was increased up to 87.8 AE 5.7%. However, various concentrations of KRG-TS (25e150 mg/mL) significantly reduced thrombin-stimulated platelet aggregation in a dosedependent manner (Fig. 1C) , and its half-maximal inhibitory concentration (IC 50 ) was approximately 45 mg/mL (Fig. 1D ). This IC 50 is low compared with that (81 mg/ml) by rat platelets [18] . In addition, Washed human platelets (10 8 /mL) were preincubated with KRG-TS (150 mg/mL) in the presence of PKA inhibitor (Rp-8-Br-cAMPS) or PKG inhibitor (Rp-8-Br-cGMPS) for 3 min at 37 C, and then thrombin (0.05 U/mL) was added. Data are expressed as the mean AE standard deviation (n ¼ 4). *p < 0.05 versus the thrombin-stimulated human platelets. **p < 0.05 versus the thrombin-stimulated platelets in the presence of KRG-TS (150 mg/mL). ] i is essential for platelet aggregation, we investigated the effect of KRG-TS on thrombin-induced platelet aggregation in the presence of PKA or PKG inhibitor, both of which are intracellular Ca 2þ -antagonistic compounds. As shown in Fig. 2A , thrombin increased light transmission [ Fig. 2A(a) ], whereas KRG-TS decreased thrombin-induced light transmission [ Fig. 2A(d) ] i level from 101.2 AE 0.5nM (basal level) to 590.6 AE 18.3nM (Fig. 3A, inset  table) . However, this was significantly decreased by various concentrations (25e150 mg/mL) of KRG-TS in a dose-dependent manner (Fig. 3A) . If the inhibition of [Ca ] i mobilization (Fig. 3A) by KRG-TS may be more dependent on the pathway of cAMP/PKA than cGMP/PKG. We, therefore, investigated the effect of KRG-TS on phosphorylation of PKAc as an indicator of cAMP/PKA activation.
Effects of KRG-TS on PKAc (Thr 197 ) phosphorylation
It is well-known that the phosphorylation of PKAc (Thr 197 ) is necessary to produce biological functions through the cAMP/PKA pathway [23] . As shown in (Fig. 5, lane 4) , we used the PKA inhibitor Rp-8-Br-cAMPS (Fig. 4, lane 6 (Fig. 3A) , we investigated whether KRG-TS is involved in the inhibition of ATP and serotonin release. As shown in Fig. 6 , KRG-TS dose dependently inhibited thrombin-induced ATP (Fig. 6A ) and serotonin release (Fig. 6C) . Because the inhibition of [Ca 2þ ] i mobilization by KRG-TS was dependent on cAMP/PKA and cGMP/PKG pathways, we investigated whether the inhibition of ATP and serotonin release by KRG-TS resulted from cAMP/PKA and cGMP/PKG pathways. The PKA inhibitor Rp-8-Br-cAMPS (Fig. 6B ) and the PKG inhibitor Rp-8-Br-cGMPS (Fig. 6D ) increased KRG-TS-decreased ATP and serotonin release. These results indicate that the inhibition of ATP and serotonin release by KRG-TS (Figs. 6A and 6C) is dependent on the cAMP/PKA and cGMP/PKG-pathways. The results are supported by the fact that the PKA activator pCPT-cAMP (Fig. 6B) and the PKG activator 8-BrcGMP (Fig. 6D ) inhibit thrombin-induced ATP and serotonin release.
Effects of ginsenosides in KRG-TS on thrombin-induced platelet aggregation
In a previous report [18] , five ginsenosides (G-Rb1, G-Rb2, G-Rc, G-Rd, and G-Rg3) were reported as 20(S)-PPDS and three ginsenosides (G-Re, G-Rg1, and G-Rg2) as 20(S)-PPTS. Besides these ginsenosides, it is known that G-Ra1, G-Rb3, and G-Rh2 as PPDS and G-Rf and G-Rh1 as PPTS are also present in P. ginseng [25] . Therefore, to investigate which ginsenoside of KRG-TS was involved in the inhibition of thrombin-induced human platelet aggregation, we investigated the effect of ginsenosides in KRG-TS and other ginsenosides on thrombin-induced human platelet aggregation. In this study, G-Ra1, G-Rb1, G-Rb2, G-Rb3, G-Rc, G-Rd, and G-Rh2(20R) of PPDS did not inhibit thrombin-induced human platelet aggregation, but only G-Rg3 (20R, 20S) dose dependently inhibited thrombin-induced human platelet aggregation (Table 3 ). In addition, none of the PPTSs [G-Re, G-Rf, G-Rg1, G-Rg2 (20R), and G-Rh1 (20S)] inhibited thrombin-induced human platelet aggregation (Table 4 ).
Discussion
Although KRG-TS elevated cAMP only in thrombin-induced human platelets [17] , to confirm whether the cAMP/PKA or cGMP/PKG pathway contributed to the inhibition of platelet aggregation by KRG-TS, we investigated the effect of PKA inhibitor and PKG inhibitor on thrombin-induced human platelet aggregation in the presence of KRG-TS. The results showed that the PKA inhibitor Rp-8-Br-cAMPS and the PKG inhibitor Rp-8-Br-cGMPS increased KRG-TS-decreased light transmission in thrombininduced human platelet aggregation. However, the elevation of light transmission by the PKA inhibitor was stronger than that by the PKG inhibitor in KRG-TS-inhibited thrombin-induced human platelet aggregation. These results show that the cAMP/PKA pathway mainly contributed to the inhibition of thrombin-induced platelet aggregation and [Ca ] i through the G-protein-coupled receptor/ PLC-b pathway, and constricts the blood vessel tract [5,26e28] , which enforces thrombus formation. Therefore, the inhibition of [Ca 2þ ] i mobilization by IP 3 and TXA 2 production by COX-1/TXAS are very important to evaluate the antiplatelet effect of a substance. A previous report [17] confirmed that KRG-TS inhibits TXA 2 Results are expressed as percentage of aggregation induced by thrombin. The data are expressed as the mean AE standard deviation (n ¼ 4) *p < 0.05, **p < 0.01 versus the thrombin-stimulated human platelets ). Platelet aggregation is generated at the site of vascular wall injury, and is involved in the formation of thrombus. During the formation of thrombus, platelets release cell growth proteins [e.g., platelet-derived growth factor (PDGF)] and vascular endothelial growth factor (VEGF) in a-granules [30, 31] . It is well-established that PDGF and VEGF induce the proliferation of fibroblast, vascular smooth cells, and epithelial cells, and subsequently enhance the rate of atherosclerosis lesion progression [32e36]. The progression of atherosclerosis is strongly induced by inflammatory cells such as monocytes/macrophages and neutrophils [37] . Although KRG-TS shows antiplatelet effects, if KRG-TS does not inhibit inflammation by leukocytes, progression of atherosclerosis lesion occurs at the site of vascular wall injury, which raises questions about the antiplatelet effects of KRG-TS. Byeon et al [38] reported that saponin fraction inhibits lipopolysaccharide (LPS)-induced inflammation, and it is well-known that ginsenosides exhibit anti-inflammatory effects by inhibiting the production of various proinflammatory mediators such as prostaglandin E 2 and NO [39] . Recently, it was reported that saponin fractions of KRG downregulate LPS-induced proinflammatory mediators (i.e., NO and interleukin-1b) [40] . Considering these three previous reports [38e40], it is thought that KRG-TS may exhibit antithrombotic and antiatherosclerotic effects without causing inflammation and progression of atherosclerotic lesion at the site of vascular wall injury. Therefore, KRG-TS is highlighted as a "nontoxic antiplatelet compound," and could be clinically applied to the prevention of platelet-mediated thrombosis. This result is supported by a previous study suggesting the protective effects of KRG on carotid artery thrombosis in vivo in rats [41] . In addition, both ginseng and ginsenosides are very useful for prevention of cardiovascular disease [42] .
With regard to the antiplatelet effects of ginsenosides in KRG-TS, only G-Rg3 (20R, 20S) inhibited thrombin-induced platelet aggregation. This is in accordance with the reports that G-Rg3 (20R, 20S) inhibited arachidonic acid-or U46619-induced platelet aggregation [43] , and its analog (G-Rp1, dihydroxy G-Rg3) inhibited collagen-or thrombin-induced platelet aggregation [19, 20] . Other reports also suggested that G-Rg1 [molecular weight (MW) ¼ 800.94] and GRg2 (MW ¼ 781.01) inhibit various agonists (i.e., thrombin, collagen, ADP)-induced platelet aggregation [44e46], but the inhibitory concentrations were 1 mg/mL (1.2mM) to 4 mg/mL (5mM) for G-Rg1 [44, 45] and 1 mg/mL (1.3mM) for G-Rg2 [45, 46] . These inhibitory concentrations (1.2e5mM) of G-Rg1 or G-Rg2 (1.3mM) [44e46] are very high compared with those of G-Rg3 and its analogues (G-Rp1, dihydroxy G-Rg3), which exhibited antiplatelet effect at concentrations in the range of micromoles [19, 20, 43] . Therefore, it is thought that the antiplatelet effects exhibited by G-Rg1 and G-Rg2 should be re-evaluated. Because only G-Rg3 in KRG-TS inhibited thrombin-induced human platelet aggregation, it is thought that G-Rg3 in KRG-TS might have contributed to the inhibition of platelet aggregation and [Ca 2þ ] i mobilization, which also supports the report that G-Rg3 elevated Ca 2þ -antagonistic cAMP levels [20] . Thrombosis mainly results from the irreversible aggregation, which is closely related to the serotonin released from platelets activated by agonists (i.e., collagen and thrombin) [47e49] . In addition, the released serotonin is involved in causing migraine [50e52].
In conclusion, the most important result of this study is that KRG-TS significantly phosphorylates IP 3 RI (Ser 1756 ) to inhibit thrombin-induced [Ca 2þ ] i mobilization, which contributed to attenuating the release of ATP and serotonin. Therefore, our results suggest that KRG-TS may be a physiologically effective negative regulator in platelet aggregation, a cause of thrombosis, atherosclerosis, and myocardial infarction. Because KRG-TS also inhibits serotonin release, it should also be evaluated as an antimigraine substance.
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